These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

60 related items for PubMed ID: 9597521

  • 1. Safe use of platelet GP IIb/IIIa inhibitors.
    Ferguson JJ, Kereiakes DJ, Adgey AA, Fox KA, Hillegass WB, Pfisterer M, Vassanelli C.
    Eur Heart J; 1998 Apr; 19 Suppl D():D40-51. PubMed ID: 9597521
    [Abstract] [Full Text] [Related]

  • 2. Safe use of platelet GP IIb/IIIa inhibitors.
    Ferguson JJ, Kereiakes DJ, Adgey AA, Fox KA, Hillegass WB, Pfisterer M, Vassanelli C.
    Am Heart J; 1998 Apr; 135(4):S77-89. PubMed ID: 9539498
    [Abstract] [Full Text] [Related]

  • 3. Use of abciximab in interventional cardiology.
    Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D, van Hout BA.
    Eur Heart J; 1998 Apr; 19 Suppl D():D31-9. PubMed ID: 9597520
    [Abstract] [Full Text] [Related]

  • 4. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E, Maseri A, Armstrong PW, Califf RM, Gibler WB, Hamm CW, Simoons ML, Van de Werf F.
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [Abstract] [Full Text] [Related]

  • 5. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA.
    Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH, Chen JW, Wu TC, Ding PY, Wang SP, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
    [Abstract] [Full Text] [Related]

  • 7. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L, TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.
    N Engl J Med; 2001 Jun 21; 344(25):1888-94. PubMed ID: 11419425
    [Abstract] [Full Text] [Related]

  • 8. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJ.
    N Engl J Med; 1999 Jul 29; 341(5):319-27. PubMed ID: 10423466
    [Abstract] [Full Text] [Related]

  • 9. Use of abciximab in interventional cardiology.
    Chronos N, Vahanian A, Betriu A, Emanuelsson H, Goldberg S, Gulba D, van Hout BA.
    Am Heart J; 1998 Apr 29; 135(4):S67-76. PubMed ID: 9539497
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel.
    Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PP, Schömig A, Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators.
    Circulation; 2004 Dec 14; 110(24):3627-35. PubMed ID: 15531766
    [Abstract] [Full Text] [Related]

  • 13. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M, Ruf A, Neumann FJ, Pogátsa-Murray G, Dickfeld T, Zohlnhöfer D, Schömig A.
    Thromb Haemost; 1998 Dec 14; 80(6):994-1001. PubMed ID: 9869173
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM, Topol EJ.
    Eur Heart J; 2000 Jun 14; 21(11):863-7. PubMed ID: 10806004
    [No Abstract] [Full Text] [Related]

  • 16. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB, Grines CL, Bittl JA, Becker RC, Kereiakes DJ, Gilchrist IC, Clegg J, Stankowski JE, Grogan DR, Harrington RA, Emanuelsson H, Weaver WD.
    Am Heart J; 2006 Mar 14; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B).
    Mukherjee D, Mahaffey KW, Moliterno DJ, Harrington RA, Yadav JS, Pieper KS, Gallup D, Dyke C, Roe MT, Berdan L, Lauer MS, Mänttäri M, White HD, Califf RM, Topol EJ.
    Am Heart J; 2002 Dec 14; 144(6):995-1002. PubMed ID: 12486423
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of abciximab on acute myocardial infarction treated with percutaneous coronary interventions: a meta-analysis of randomized, controlled trials.
    de Queiroz Fernandes Araújo JO, Veloso HH, Braga De Paiva JM, Filho MW, Vincenzo De Paola AA.
    Am Heart J; 2004 Dec 14; 148(6):937-43. PubMed ID: 15632875
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.